Financials
Financial year 2024
Gross margin
€ 94,120
▼ 39% vs 2023
Profit
Growing€ 65,307
▲ 9% vs 2023
Debts
Low€ 772,606
▼ 15% vs 2023
DGPharma from Gent, company number BE0508925544, closed financial year 2024 with a result of € 65,307 after tax. For that financial year DGPharma recorded a gross margin of € 94,120 and equity of € 571,787. Compared with financial year 2023, the result moved from € 59,780 to € 65,307. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2025.
What happened at DGPharma?
What happened at DGPharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 65,307 (▲ 9% vs 2023). Source: NBB ↗
- AQUITANIA BV became a director. NBB
- CREDOPHAR BV became a director. NBB
- FARMAFENDER BV became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 114,141 profit in 2021 to € 65,307 profit in 2024.
Paid € 98,255 in corporate taxes since 2021.
Best year ever: 2021, with € 114,141 profit.
Paid out € 100,000 in dividends to the owners in total.
A new publication or filing at DGPharma? We notify you, reason included.
Follow DGPharmaNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind DGPharma are AQUITANIA BV, CREDOPHAR BV and FARMAFENDER BV. The same people are also behind Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium, Labophar and 2PHARMA HOLDING.
Directors
According to the 2024 annual accounts
Director · represented by IMSCHOOT ANJA
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium +6 more
since 2022
since 2022
Director · represented by VAN PETEGHEM BRAM
Also active at: b+pharma Belgium, Labophar
since 2022
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
Ceres Pharmaceuticals same network
€ 14.6 million revenue · 2025
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
b+pharma Belgium same network
€ 287,023 gross margin · 2025
Ceres Pharma
€ 35.3 million revenue · 2025
+15 more
Details
- Company number
- 0508.925.544
- VAT number
- BE 0508.925.544
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- DGPharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 December 2012
- Peppol
- Active · Active since 1 Aug 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Overige detailhandel in voedingsmiddelen, neg
Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Groothandel in andere voedingsmiddelen, neg
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering